Archive | January, 2012

Assessment of Studies of Health Outcomes Related to the Recommended Childhood Immunization Schedule

31 Jan

The U.S. Institutes of Medicine (IOM) will hold a meeting to discuss the feasibility of studying health outcomes in vaccinated and unvaccinated children. Health Outcomes Related to the Recommended Childhood Immunization Schedule will be held on February 9.

Activity Description

The IOM will conduct an independent assessment surrounding the feasibility of studying health outcomes in children who were vaccinated according to the CDC recommended schedule and those who were not (e.g. children who were unvaccinated or vaccinated with an alternate schedule). The IOM will review scientific findings and stakeholder concerns related to the safety of the recommended childhood immunization schedule. Further, the IOM will identify potential research approaches, methodologies, and study designs that could inform this question, including an assessment of the potential strengths and limitations of each approach, methodology and design, as well as the financial and ethical feasibility of doing them. A report will be issued in mid-2012 summarizing the IOM’s findings and conclusions.

Here is the draft agenda:

Draft Agenda
11:00-12:00 OPEN SESSION

11:00-11:15 Welcome and Overview
Ada Sue Hinshaw, Ph.D., R.N.
Committee Chair

11:15-11:35 Presentation of the Charge from the National Vaccine Program Office
Bruce Gellin, M.D., M.P.H.
Deputy Assistant Secretary for Health
Director, National Vaccine Program Office, US Department of
Health and Human Services

11:35-12:00 Review of IOM’s Committee to Review Adverse Effects of Vaccines
Ellen Wright Clayton, J.D., M.D.
Chair of the IOM Committee to Review Adverse Effects of
Vaccines
Craig-Weaver Professor of Pediatrics, Vanderbilt University

12:00-1:00 CLOSED SESSION –WORKING LUNCH

1:00-5:00 OPEN SESSION

1:00-1:20 National Vaccine Information Center Perspectives
Barbara Loe Fisher
Co-Founder & President, National Vaccine Information Center

1:20-1:40 Provider Perspectives
Gary Freed, M.D., M.P.H.
Professor, Department of Health Management and Policy,
University of Michigan School of Public Health
Director, Division of General Pediatrics
The Percy and Mary Murphy Professor of Pediatrics and Child
Health Delivery

1:40-2:00 The Use of Clinical Trials for Childhood Vaccines
Susan Ellenberg, Ph.D.
Professor of Biostatistics and Associate Dean for Clinical
Research
Perelman School of Medicine at the University of Pennsylvania

2:00-2:20 Ethical Issues in Clinical Trials
Robert (Skip) Nelson, M.D., Ph.D.
Senior Pediatric Ethicist/Lead Medical Officer, Food and Drug
Administration

2:20-2:40 BREAK

2:40-3:05 National Center for Immunization and Respiratory Diseases (NCIRD)
Centers for Disease Control and Prevention (CDC)
Melinda Wharton M.D., M.P.H.
Deputy Director, NCIRD, CDC
Captain, US Public Health Services

3:05-3:25 Immunization Safety Office (ISO) CDC
Frank DeStefano, M.D., M.P.H.
Director, ISO, CDC

3:25-3:45 Data and Approaches in National and International Immunization Studies
Saad Omer, Ph.D., M.P.H., M.B.B.S
Assistant Professor, Hubert Department of Global Health
Epidemiology, Emory University Rollins School of Public Health
Assistant Professor, Emory Vaccine Center

3:45-4:05 Immune Profiling Research
Chuck Hackett, Ph.D.
Deputy Director, Division of Allergy, Immunology, and
Transplantation
National Institute of Allergy and Infectious Disease

4:05-5:00 OPEN SESSION* — Opportunity for Attendee Comments

5:00 ADJOURN

Joint ASAN-Autism Society Statement on DSM 5

31 Jan

Below is a joint statement by the Autistic Self Advocacy Network and the Autism Society of America on the DSM-5.

Dear Friend,

As two national organizations committed to working to empower the autism and Autistic communities today and into the future, the Autism Society of America and the Autistic Self Advocacy Network issue the following joint statement regarding the definition of Autism Spectrum Disorder within the DSM-5:

The autism spectrum is broad and diverse, including individuals with a wide range of functional needs, strengths and challenges. The DSM-5’s criteria for the new, unified autism spectrum disorder diagnosis must be able to reflect that diversity and range of experience.

Over the course of the last 60 years, the definition of autism has evolved and expanded to reflect growing scientific and societal understanding of the condition. That expansion has resulted in improved societal understanding of the experiences of individuals on the autism spectrum and their family members. It has also led to the development of innovative service-provision, treatment and support strategies whose continued existence is imperative to improving the life experiences of individuals and families. As the DSM-5’s final release approaches and the autism and Autistic communities prepare for a unified diagnosis of ASD encompassing the broad range of different autism experiences, it is important for us to keep a few basic priorities in mind.

One of the key principles of the medical profession has always been, “First, do no harm.” As such, it is essential that the DSM-5’s criteria are structured in such a way as to ensure that those who have or would have qualified for a diagnosis under the DSM-IV maintain access to an ASD diagnosis. Contrary to assertions that ASD is over diagnosed, evidence suggests that the opposite is the case – namely, that racial and ethnic minorities, women and girls, adults and individuals from rural and low-income communities face challenges in accessing diagnosis, even where they clearly fit criteria under the DSM-IV. Furthermore, additional effort is needed to ensure that the criteria for ASD in the DSM-5 are culturally competent and accessible to under-represented groups. Addressing the needs of marginalized communities has been a consistent problem with the DSM-IV.

Individuals receive a diagnosis for a wide variety of reasons. Evidence from research and practice supports the idea that enhancing access to diagnosis can result in substantial improvements in quality of life and more competent forms of service-provision and mental health treatment. This is particularly true for individuals receiving diagnosis later in life, who may have managed to discover coping strategies and other adaptive mechanisms which serve to mask traits of ASD prior to a diagnosis. Frequently, individuals who are diagnosed in adolescence or adulthood report that receiving a diagnosis results in improvements in the provision of existing services and mental health treatment, a conceptual framework that helps explain past experiences, greater self-understanding and informal support as well as an awareness of additional, previously unknown service options.

Some have criticized the idea of maintaining the existing, broad autism spectrum, stating that doing so takes limited resources away from those most in need. We contend that this is a misleading argument – no publicly funded resource is accessible to autistic adults and children solely on the basis of a diagnosis. Furthermore, while the fact that an individual has a diagnosis of autism spectrum disorder does not in and of itself provide access to any type of service-provision or funding, a diagnosis can be a useful contributing factor in assisting those who meet other functional eligibility criteria in accessing necessary supports, reasonable accommodations and legal protections. As such, we encourage the DSM-5 Neurodevelopmental Disorders Working Group to interpret the definition of autism spectrum disorder broadly, so as to ensure that all of those who can benefit from an ASD diagnosis have the ability to do so.

The Autism Society and Autistic Self Advocacy Network encourage other organizations and groups to join with us in forming a national coalition aimed at working on issues related to definition of the autism spectrum within the DSM-5. Community engagement and representation within the DSM-5 process itself is a critical component of ensuring accurate, scientific and research-validated diagnostic criteria. Furthermore, our community must work both before and after the finalization of the DSM-5 to conduct effective outreach and training on how to appropriately identify and diagnose all those on the autism spectrum, regardless of age, background or status in other under-represented groups.

Sincerely,
Ari Ne’eman
President of
Autistic Self Advocacy Network
aneeman@autisticadvocacy.org

Scott Badesch
President of
Autism Society
sbadesch@autism-society.org

Generation Rescue’s tax form 990 for 2010

31 Jan

Generation Rescue’s tax forms (form 990) for 2010 have been made publicly available.

2010 was the second highest year financially for Generation Rescue. Here are their yearly totals:

2006: $318,695
2007: $425,317
2008: $1,185,255
2009: $623,597
2010: $1,078,471

GENERATION RESCUE IS DEDICATED TO RECOVERY FOR CHILDREN WITH AUTISM SPECTRUM DISORDERS BY PROVIDING GUIDANCE AND SUPPORT FOR MEDICAL TREATMENT

The largest expense was for “research”: $307,439. The description is not very detailed:

GR CONTINUES ITS COMMITMENT TO DISCOVERING THE CAUSES OF AUTISM SPECTRUM DISORDERS AS A MEANS OF IMPROVING TREATMENTS AND QUALITY OF LIFE, WHILE WORKING TOWARDS A PREVENTION AND A CURE. ANGELS DONATE THEIR TIME TO ANSWER QUESTIONS, GIVE GUIDANCE AND PROVIDE RESOURCES FOR FAMIILIES STARTING OUT ON THEIR OWN.

More on this later.

Other expenses? Marketing and Awareness, for one: $135,128

MARKETING & AWARENESS
GR IS DEDICATED TO SPREADING AWARENESS AND INFORMATION ABOUT AUTISM TO THE POPULATION AT LARGE, TO ENSURE THE UNDERSTANDING AND SUPPORT FOR THE DISORDER. GR WORKS CLOSELY ON A GRASSROOTS AND NATIONAL LEVEL TO ENGAGE FAMILIES IN THE PROCESS.

Rescue Family Grant Program: $96, 431

GR’S RESCUE FAMILY GRANT PROGRAM PROVIDES AUTISM TREATMENT SUPPORT TO INDIVIDUALS AND FAMILIES AFFECTED BY AUTISM SPECTRUM DISORDERS. GR PROUDLY PROVIDES FAMILIES WITH THIS UNIQUE AUTISM TREATMENT PROGRAM, WHICH MAY NOT OTHERWISE BE COVERED BY SCHOOL DISTRICTS, COUNTY PROGRAMS, INSURANCE OR OTHER GRANT-GENERATING ENTITIES.

Other program services: $328,660.

You may recall that this year Generation Rescue teamed up with AutismOne to produce the AutismOne conference. They made the conference “free” to attendees (with a $25 fee). Generation Rescue put out $76,467 to support the conference. Someone is obviously paying (exhibitors? Speakers?), Generation Rescue made $38,883 on the conference. Compare this with their comedy event where they spent $98,422 to make $15,327. Autism One is a much better deal for them.

Remember those research expenses mentioned above? I assume that this charge is included there: “Strategic Autism Initiative” got $100,000 “for researching the causes of autism:”. What’s the Strategic Autism Initiative? Simply put: Andrew Wakefield. That’s the organization he created after leaving Thoughtful House. Been wondering how Andrew Wakefield is paying the bills since losing that job? Well this gives you a big clue.

(For comparison, their “Family Grant” program received less money: $93,122 for 111 recipients.)

Under compensated board members, officers, etc., they list:

Jenny McCarthy, President, Director (10 hours/week, no pay)
Jonathan B Handley, Director (10 hours/week, no pay)
Lisa Handley, Director (10 hours/week, no pay)
and
Candace MacDonald, Executive Director (40 hours/week, $128,613)

Total in salaries and other compensation $260,569. (in 2009, this was $364,686)

Generation Rescue’s mission statement for 2010?

GENERATION RESCUE (GR) IS DEDICATED TO RECOVERY FOR CHILDREN WITH AUTISM SPECTRUM DISORDERS BY PROVIDING GUIDANCE AND SUPPORT FOR MEDICAL TREATMENT TO DIRECTLY IMPROVE THE CHILD’S QUALITY OF LIFE FOR ALL FAMILIES IN NEED

This has been evolving.

2009:

GENERATION RESCUE,INC IS AN INTERNATIONAL MOVEMENT 0F SCIENTISTS AND PHYSICIANS RESEARCHING THE CAUSES AND TREATMENTS FOR AUTISM, ADHD, AND CHRONIC ILLNESS WHILE PARENT-VOLUNTEERS MENTOR THOUSAND OF FAMILIES IN RECOVERING THEIR CHILDREN

2008:

CONTINUING RESEARCH, EDUCATION AND DISSEMINATION OF INFORMATION TO THE GENERAL PUBLIC AND MEDICAL PROFESSIONAL RELATING TO MERCURY TOXICITY AND ITS EFFECT ON CHILD DEVELOPMENT

(Generation started out as a major proponent of the idea that autism was a misdiagnosis for mercury poisoning)

One might notice that the “research” budget is significantly higher than that allocated to Mr. Wakefield’s organization. They allocate $307,439 for research. Compare this to 2009, when their support of research appears to be a single entry of $30,000 given to the HEAL Foundation.

$100,000 is going to Mr. Wakefield. Where is the other $208,439 going? Generation Rescue at one point felt they could do a vaccinated/unvaccinated study for $809,721. At that time it was proposed as a 2 year study. Is it in the works?

Does MMR vaccine travel in time?

27 Jan

The news that the diagnosis of autism may be brought forward is primarily of importance because it may help identify children who will require specialised support. However, it is also interesting because it breaks the co-incidental temporal association that has been part of the reason the MMR vaccine-autism hypothesis gained traction. Since the behavioural cues for autism can’t be picked up well until after one year of age, parental concern about their child being different and autism diagnoses rose after administration of the MMR vaccine. This had unfortunate consequences for the perception of MMR vaccine’s safety.

Elsabbagh et al examined “brainwaves” (event-related potentials – ERPS) of babies with a familial risk of autism when presented with pictures of faces either gazing at the baby or away from the baby. Those children who went on to develop autism diagnoses had differing ERPs.

Although the evidence of fraud, failure to find epidemiological evidence to back-up Wakefield’s claims, and failure to find measles RNA that would have supported Wakefield’s work were enough to bury any scientific case for the MMR Vaccine-autism hypothesis, the fact that autism may now be diagnosed before the MMR vaccine lays a nice wreath on top.

Not all parents whose children developed autism blamed MMR vaccine, some parents were already aware of a “difference” about their child before MMR vaccine, but it is understandable how some parents would have made the connection with the vaccine. After all, it is a key part of how clinicians make connections between a drug and adverse event, and is a strong element of assessing causality (see Bradford-Hill criteria).

The causation in the MMR vaccine debacle was neatly illustrated in an article from Prescriber [Registration required] written by Paula McDonald (a former Consultant in Communicable Disease Control).

Some of these syllogisms may be plausible to some patients

Aristotle’s concept of syllogisms, says if certain prepositions are met, something distinct will arise from necessity. However, he also noted false syllogisms (In the UK we have an entire publication devoted to generating them, called the Daily Mail). McDonald’s figure illustrates the usual example of the horse being classified as a cat, along with the example of teddy bears and MMR vaccine causing autism.

You could replace the teddy bears with Peppa the Pig, or some other Greenfieldian scare. However, it sounds more convincing with vaccines, afterall you are introducing foreign material into a healthy child (and vaccines do cause adverse events sometimes).

Convincing people a false syllogism is wrong is a lot harder, than pointing out that A could not have caused B, because B arose months before A happened. Temporal associations are how we make sense of the everyday world. We don’t blame tripping up on a kerb on the beer we were going to have in the pub later that night.

Barring a Skynet conspiracy to send Terminators with MMR vaccine back in time to cause autism, this looks like a useful point to make to parents concerned about the risk of autism with MMR vaccine. Quite what the anti-vaccination groups will do, like the UK JABS cult, is interesting. Perhaps they will move to attack other vaccines given earlier, such as meningitis C or diptheria? Alternatively, they may look to the misapplication of physics, perhaps taking comfort in the news that neutrinos may have travelled faster than light, as their comrades-in-arms the homeopaths did.

Cross posted at Black Triangle.

Infant Neural Sensitivity to Dynamic Eye Gaze Is Associated with Later Emerging Autism

27 Jan

A study out today is causing much discussion. Infant Neural Sensitivity to Dynamic Eye Gaze Is Associated with Later Emerging Autism is by researchers from the UK, Canada and Australia:

1 Centre for Brain and Cognitive Development, Birkbeck College, University of London, London WC1E 7HX, UK
2 Department of Psychiatry, McGill University, Montreal, Quebec H3A 1A1, Canada
3 Olga Tennison Autism Research Centre, School of Psychological Science, La Trobe University, Bundoora, Victoria 3086, Australia
4 Centre for Research in Autism and Education, Institute of Education, University of London, London WC1H 0AL, UK
5 Institute of Psychiatry, King’s College London, London SE5 8AF, UK
6 Autism Research Centre, University of Cambridge, Cambridge CB2 8AH, UK

In Study finds early signs of autism in baby brains, Fox News and Reuters report the study:

Children who develop autism already show signs of different brain responses in their first year of life, scientists said on Thursday in a study that may in the future help doctors diagnose the disorder earlier.

British researchers studied 104 babies at 6 to 10 months and then again at 3-years-old, and found that those who went on to develop autism had unusual patterns of brain activity in response to eye contact with another person.

The BBC in their story Autism: Brainwaves ‘show risk from age of six months’, notes:

Prof Johnson said: “It is important to note it is not a 100% predictor. We had babies who flagged up warning signs who did not develop autism.”

There were also babies who did develop autism who had low-risk brainwaves. The test would need to be more accurate before it was used routinely.

And this is a big reason I’d like to see the actual study. How accurate was this measure?

I would point out that there are children who show very clear behavioral signs of autism before age 1, something which the news stories don’t seem to be capturing.

Autistica, who helped fund the research, included this in their comment on the study:

In their first year of life, babies who will go on to develop autism already show different brain responses when someone looks at them or away. Although the researchers are careful to say that the study is only a first step toward earlier diagnosis, the findings do suggest that direct brain measures might help to predict the future development of autism symptoms in infants as young as six months.

“Our findings demonstrate for the first time that direct measures of brain functioning during the first year of life associate with a later diagnosis of autism – well before the emergence of behavioural symptoms,” said Professor Mark Johnson, MRC Scientist and head of the Centre for Brain and Cognitive Development at Birkbeck, University of London.

“Our findings demonstrate for the first time that direct measures of brain functioning during the first year of life associate with a later diagnosis of autism – well before the emergence of behavioural symptoms,” said Professor Mark Johnson, MRC Scientist and head of the Centre for Brain and Cognitive Development at Birkbeck, University of London.

I have not seen nor read the paper yet. The abstract is available and they give “highlights” of the study:

Highlights
Family risk for autism confers subtle differences in brain function in infants
Atypical ERPs in infants when viewing eye gaze data associates with later autism diagnosis
Robust prediction of autism will require an understanding of risk and protective factors

and the summary:

Summary

Autism spectrum disorders (henceforth autism) are diagnosed in around 1% of the population [1]. Familial liability confers risk for a broad spectrum of difficulties including the broader autism phenotype (BAP) [2,3]. There are currently no reliable predictors of autism in infancy, but characteristic behaviors emerge during the second year, enabling diagnosis after this age [4,5]. Because indicators of brain functioning may be sensitive predictors, and atypical eye contact is characteristic of the syndrome [6,7,8,9] and the BAP [10,11], we examined whether neural sensitivity to eye gaze during infancy is associated with later autism outcomes [12,13]. We undertook a prospective longitudinal study of infants with and without familial risk for autism. At 6–10 months, we recorded infants’ event-related potentials (ERPs) in response to viewing faces with eye gaze directed toward versus away from the infant [14]. Longitudinal analyses showed that characteristics of ERP components evoked in response to dynamic eye gaze shifts during infancy were associated with autism diagnosed at 36 months. ERP responses to eye gaze may help characterize developmental processes that lead to later emerging autism. Findings also elucidate the mechanisms driving the development of the social brain in infancy.

Here is Figure 1 from the article, which I admit in this version is too small to be very illustrative:

But the figure caption gives some more details about the actual study.

Figure 1. Association between Infant ERPs in Response to Eye Gaze and Autism Outcomes(A) Participating families first visited the lab when their infants were 6–10 months of age. Electrophysiological recording was done during this visit. Infants were prepared for the EEG session.(B) Electrophysiological response to gaze shifts over occipitotemporal channels.(C) Around 2 and 3 years of age, the same infants were tested by an independent team using several measures including the ADOS, a semistructured observational measure of autism-related characteristics. Based on information from all visits, combined with expert clinical judgment, infants in the at-risk group were classified as having ASD or not.(D) Controlling for age at the first visit, significant condition × risk-group interactions were observed for the amplitude of the P400 [F(1,92) = 6.7, p = 0.01]; planned post hoc tests focused on within-group difference between response to direct versus averted gaze controlling for age at baseline and developmental level at 36 months. Estimated mean differences between responses to gaze toward versus away are displayed for each group (standard error bars are displayed). Findings suggest that differentiation between gaze toward versus away was reliable in the both the control group (p < 0.001) and the at-risk without ASD group (p = 0.04). By contrast, the at-risk group that developed ASD showed no differentiation (p = 0.67) nor did the subgroup that developed early and persistent symptoms (p = 0.27). Findings from static face and face versus noise contrasts are presented in Figure S1 and Table S1.

The DSM 5 and autism

24 Jan

A recent article in the New York Times has sparked a renewed heated discussion on the topic of Autism and how the DSM 5 may change how it is diagnosed. The Times article, New Definition of Autism Will Exclude Many, Study Suggests, has already been discussed here at Left Brain/Right Brain.

At that time there was a paragraph from the Times which was troubling:

The changes would narrow the diagnosis so much that it could effectively end the autism surge, said Dr. Fred R. Volkmar, director of the Child Study Center at the Yale School of Medicine and an author of the new analysis of the proposal. “We would nip it in the bud.”

Unfortunately we don’t have the full quote from Prof. Volkmar. The whole thing seemed a little strange. As noted on the Embargo Watch blog, this was based on a talk given at a small conference and a single slide in that talk.
In my opinion, it looks like the Times ran with a story that they shouldn’t have, and may have made it appear more troubling than it really is.

Troubling in this respect: the point of the DSM in my opinion is not to try to manage one way or another the number of identified autistics. It should be to accurately identify autistics.

A later article in the Times had this paragraph, which is again bothersome:

“We have to make sure not everybody who is a little odd gets a diagnosis of autism or Asperger disorder,” said Dr. David J. Kupfer, a professor of psychiatry at the University of Pittsburgh and chairman of the task force making the revisions, which are still subject to change. “It involves a use of treatment resources. It becomes a cost issue.”

I don’t see it as the place of the DSM 5 committee to either manage the “surge” in autism diagnoses or to manage a “cost issue”. And while the Times may be overplaying this, we need to focus on the fact that accuracy is far more important than social engineering here. Frankly I don’t think that everyone who is a “a little odd gets a diagnosis of autism or Asperger disorder” now. If there is a problem with over diagnosis, I’d like to see it backed up with data. Especially in the adult population, which is likely very much under diagnosed.

There are two valuable outcomes to accurately diagnosing autism. First and foremost is in providing services. In this respect it is better to cast the net a little wide rather than miss people who are in need. I don’t think we are there yet. As of now there may be an under count of autistic students based on socioeconomic status:

If the SES gradient found in this study is due only to ascertainment bias, this would imply that there are significant SES disparities in access to diagnostic and other services for children with autism in communities across the United States. It also would imply that the current estimate of ASD prevalence might be substantially undercounted, with children of low and medium SES being under-identified and underserved relative to those with high SES.

Girls may be identified later than boys:

Girls, especially those without cognitive impairment, may be formally identified at a later age than boys. This may delay referral for early intervention. Community education efforts should alert clinicians and parents to the potential of ASDs in boys and girls.

Autism is underdiagnosed in racial/ethnic minorities.

Significant racial/ethnic disparities exist in the recognition of ASD. For some children in some racial/ethnic groups, the presence of intellectual disability may affect professionals’ further assessment of developmental delay. Our findings suggest the need for continued professional education related to the heterogeneity of the presentation of ASD.

And this ignores the huge elephant in the room: the fact that autism is under diagnosed in adults. When an autism prevalence study was conducted in the UK, adults identified in the diagnostic assessment part of the study were previously undiagnosed. Studies in the U.S. have identified undiagnosed autistics within institutions–a place where the individuals are under close medical supervision. Is it really a stretch to believe that the low prevalence in adults involves a lot of under counting?

There is the medical diagnosis of autism and there are legal definitions of autism. Consider California. The California Department of Developmental Services has as part of its charter providing services to autistics within the state. All well and good, but California used the same rules from about 1985 to about 2007. They waited over 10 years after the DSM-IV was implemented to revise their rules. One result of this was that individuals with autism spectrum disorder diagnoses such as PDD-NOS and Asperger syndrome were considered to be not autistic. They didn’t have “autism” as their diagnosis.

In California schools, autism is not defined by the DSM or any other medical diagnosis. It is defined legally:

(a) For purposes of this chapter, a “pupil with autism” is
a pupil who exhibits autistic-like behaviors, including, but not
limited to, any of the following behaviors, or any combination
thereof:
(1) An inability to use oral language for appropriate
communication.
(2) A history of extreme withdrawal or of relating to people
inappropriately, and continued impairment in social interaction from
infancy through early childhood.
(3) An obsession to maintain sameness.
(4) Extreme preoccupation with objects, inappropriate use of
objects, or both.
(5) Extreme resistance to controls.
(6) A display of peculiar motoric mannerisms and motility
patterns.
(7) Self-stimulating, ritualistic behavior.
(b) The definition of “pupil with autism” in subdivision (a) shall
not apply for purposes of the determination of eligibility for
services pursuant to the Lanterman Developmental Disabilities
Services Act (Division 4.5 (commencing with Section 4500) of the
Welfare and Institutions Code).

An individual without an autism (or ASD) diagnosis can be considered a “pupil with autism” (although this can be a battle). Likewise, an individual with an autism (or ASD) diagnosis can be not considered a “pupil with autism). Changing the DSM criteria will not make a difference in the educational definition. (edit to add–should have stressed “at first”. The educational definition will likely be reviewed and possibly changed after the DSM 5 is published)

An autism diagnosis is not a key to services, which is what the quotes from Professors Volkmar and Kupfer suggest (again, I think the Times has overplayed this). An autism diagnosis can often be, however, an important first step. Again in a world where legal definitions define developmental disability, having the right diagnosis can be the difference between starting the fight and being knocked out in the first round. In California the CDDS serves individuals with:

mental retardation, cerebral palsy, epilepsy, and autism. This term shall also include disabling conditions found to be closely related to mental retardation or to require treatment similar to that required for individuals with mental retardation, but shall not include other handicapping conditions that are solely physical in nature.

That last category is supposed to leave the door open to other developmental disabilities, but in practice it is a difficult argument to make. Even autism is not a key. I recall one autistic who advocated for others in the community telling me of someone who rode a bike to the DDS office for the interview. He was told he was denied because he could ride a bike. Sure its an anecdote. But at this point we don’t have a lot of data on adult autistics. And that should be a warning sign that we are under serving a big segment of the population.

And we are not talking about those “mildly affected”. I can speak from experience that the CDDS has tried to keep out one individual, my kid, someone who *clearly* meets multiple criteria.

With all due respect, I see that the DSM 5 committee holds a public trust. We need diagnostic criteria that are accurate, not designed by committee to solve problems like “cost” and a “surge” in autism.

With all this said, this latest surge in the discussion was sparked by a talk given at a conference. It is preliminary and there is a lager study in the works. There’s a reason why work like this is supposed to stay out of the public eye until complete. It appears that the author himself, Prof. Volkmar, broke the embargo on his own work, sort of. This is discussed at Embargo Watch as Study about potential effects of new autism definition spotlights the Ingelfinger Rule. Prof. Volkmar gave a single slide at a small conference and had the permission of his editor to do so. The Times picked this up and has now sparked a great fear of the DSM 5 within a large segment of the online autism communities.

The Omnibus Autism Proceeding: effectively over

21 Jan

The Omnibus Autism Proceeding (OAP) was held in the U.S. Court of Federal Claims to group the large number of claims filed involving autism and vaccines. The Docket was opened on July 3, 2002, nearly 10 years ago. The last entry was placed 1 year ago. Since then many cases have been dismissed. About half the cases are left to hear, but the fact that the two causation theories presented (that the MMR vaccine causes autism and that Thimerosal causes autism) were both found to have no merit (“not even close” one special master put it) and no new theory is proposed by the Petitioners’ Steering Committee (the attorneys who presented the case for the petitioners) makes it clear that the group claim, the omnibus, is effectively over.

That is not to say that other claims are not proceeding through the court, or that new cases will not be presented. There is at least one case pursuing the idea of mitochondrial dysfunction and autism, as with the Hannah Poling case. ([edit to add–the case ongoing, which was briefly closed, is not the Hannah Poling case. See the comments below). The case was actually dismissed for lack of action by the petitioners but the special master allowed it to continue again).

Looking back, the Omnibus peaked in 2003 when 2,437 cases were filed (close to 1/2 of the total that would eventually be filed).

Trying to avoid bullying: like a groundhog trying to run from its shadow

21 Jan

Kids get bullied, and special needs kids even more so. Doesn’t make it right. But what happens when people are so proud of it that they want it recorded to video and posted to the web?

That’s what happens in this video. A group of kids are bullying an autistic kid. Only one throws the punch, but another is ready and waiting with a cell phone camera to record the event.

http://www.abc2news.com/video/videoplayer.swf?dppversion=16926

Kaleb wants to put the bullying behind him but, as he says, “It’s like a groundhog trying to run from its shadow.’ The bully has been charged with 2nd degree assault.

New Definition of Autism May Exclude Many, Study Suggests

20 Jan

The New York Times reports New Definition of Autism May Exclude Many, Study Suggests. The study is not published yet and was presented at a conference in Iceland.

The Times reports:

The study results, presented on Thursday at a meeting of the Icelandic Medical Association, are still preliminary, but they offer the latest and most dramatic estimate of how tightening the criteria for autism could affect the rate of diagnosis. Rates of autism and related disorders like Asperger syndrome have taken off since the early 1980s, to prevalence rates as high as one in 100 children in some places. Many researchers suspect that these numbers are inflated because of vagueness in the current criteria.

The conference program doesn’t have abstracts, just paper titles. Prof. Volkmar had two talks on autism: “The Changing Face of Autism: An Introduction and Overview” and “Understanding Autism: Implications for Health Care”. This leaves us with the Times article as our source for information.

According to the Times:

In the new analysis, Dr. Volkmar, along with Brian Reichow and James McPartland, both at Yale, used data from a large 1993 study that served as the basis for the current criteria. They focused on 372 children and adults who were among the highest-functioning and found that over all, only 45 percent of them would qualify for the proposed autism spectrum diagnosis now under review. The focus on a high-functioning group may have slightly exaggerated that percentage, the authors acknowledge.

The Times has quotes from Catherine Lord (who, amongst other achievements, is one of the authors of the ADOS) who disagrees with Prof. Volkmar to some degree:

Dr. Lord said that the study numbers are probably exaggerated because the research team relied on old data, collected by doctors who were not aware of what kinds of behaviors the proposed definition requires. “It’s not that the behaviors didn’t exist, but that they weren’t even asking about them — they wouldn’t show up at all in the data,” Dr. Lord said.

The question of how the DSM 5 will change the criteria for how autism is defined has been a subject of great speculation and some study. One can find parents claiming that the DSM 5 is designed to redefine autism as only “high functioning” all the way to autistics worried that many with Asperger syndrome will no longer be classified as autistic.

The results presented by Prof. Volkmar would suggest that “classic” autism, PDD-NOS and Asperger syndrome would all see significant changes:

The likelihood of being left out under the new definition depended on the original diagnosis: About a quarter of those identified with classic autism in 1993 would not be so identified under the proposed criteria; about three quarters of those with Asperger’s would not qualify; and 85 percent of those with P.D.D.-N.O.S. would not.

As noted above, this is not the first study to consider the DSM 5 and autism. For example, a group from Finland published Autism spectrum disorders according to DSM-IV-TR and comparison with DSM-5 draft criteria: an epidemiological study. they found the DSM-5 draft criteria were ” less sensitive in regard to identification of subjects with ASDs, particularly those with Asperger’s syndrome and some high-functioning subjects with autism.”

Abstract
OBJECTIVE:

The latest definitions of autism spectrum disorders (ASDs) were specified in DSM-IV-TR in 2000. DSM-5 criteria are planned for 2013. Here, we estimated the prevalence of ASDs and autism according to DSM-IV-TR, clarified confusion concerning diagnostic criteria, and evaluated DSM-5 draft criteria for ASD posted by the American Psychiatry Association (APA) in February 2010.
METHOD:

This was an epidemiological study of 5,484 eight-year-old children in Finland, 4,422 (81%) of them rated via the Autism Spectrum Screening Questionnaire by parents and/or teachers, and 110 examined by using a structured interview, semi-structured observation, IQ measurement, school-day observation, and patient records. Diagnoses were assigned according to DSM-IV-TR criteria and DSM-5 draft criteria in children with a full-scale IQ (FSIQ) ?50. Patient records were evaluated in children with an FSIQ <50 to discover diagnoses of ASDs.
RESULTS:

The prevalence of ASDs was 8.4 in 1,000 and that of autism 4.1 in 1,000 according to DSM-IV-TR. Of the subjects with ASDs and autism, 65% and 61% were high-functioning (FSIQ ?70), respectively. The prevalence of pervasive developmental disorder not otherwise specified was not estimated because of inconsistency in DSM-IV-TR criteria. DSM-5 draft criteria were shown to be less sensitive in regard to identification of subjects with ASDs, particularly those with Asperger's syndrome and some high-functioning subjects with autism.
CONCLUSIONS:

DSM-IV-TR helps with the definition of ASDs only up to a point. We suggest modifications to five details of DSM-5 draft criteria posted by the APA in February 2010. Completing revision of DSM criteria for ASDs is a challenging task.

Comment on “Timing of Increased Autistic Disorder Cumulative Incidence”

19 Jan

In 2010 a paper was published called “Timing of increased autistic disorder cumulative incidence.” The paper has made very little, if any, impact on the scientific community. But it has become part of the stable of poor quality papers used by those claiming that vaccines caused an autism epidemic.

The paper took data from other published papers and applied a “hockey-stick” analysis to try to identify change points in the administrative prevalence of autism in California, Japan and Denmark. Here’s the main figure from that paper (click to enlarge)

Figure-1-from-Timing-paper

The idea of a hockey-stick analysis is to fit the data to two lines of different slopes which meet at a change point. Those two lines look like a hockey stick, hence the name. For multiple reasons, I believe this analysis was not appropriate for these data.

The paper is being discussed in the literature. Once by Helen Ratajczak in her review paper Theoretical aspects of autism: Causes – A review. Another citation comes from a published response to that review: Coincidental associations do not provide proof for the etiology of autism. Also “Hypothesis: Conjugate vaccines may predispose children to autism spectrum disorders“.

Two additional papers citing the Timing paper include “Mast cell activation and autism” (funded by the National Autism Association, an organization which promotes the vaccine-autism epidemic idea) and “Oxytocin and autism: a hypothesis to research. Can perinatal oxitocinergic manipulation facilitate autism?” (in Spanish).

In my view, much like Ms. Ratajczak’s review, the major impact of “Timing of Increased Autistic Disorder Cumulative Incidence” has not been in the scientific literature. An internet search quickly shows that both papers have been quite well received by those promoting vaccines as a cause of autism, both within part of the autism/parent community and from the anti-abortion community. The “Timing” paper was immediately promoted by David Kirby in an article at the Huffington Post (Mr. Kirby was a major promoter of the idea that mercury caused an autism epidemic). The paper has since been picked up by many, including Andrew Wakefield who attempts to give his interpretation of a “hockey stick” analysis in his talks (click to enlarge):

Wakefield-Jamaica

The “Timing” paper is, quite frankly, weak at best. Weak enough that I am unsure why the authors’ superiors at the EPA chose to approve it even with the disclaimer, “Approval does not signify that the contents reflect the views of the Agency” (a disclaimer which Mr. Kirby ignored as he made comments like “according to the EPA” in his piece). With much better analyses of the California Data by Peter Bearman’s group at Columbia and Irva Hertz-Picciotto‘s group at U.C. Davis, the time for such simple analyses as in the MacDonald and Paul paper is past. Especially in a highly charged area such as autism.

If I had room given the word count restrictions on a reply I would have included some of these points. Instead in “Comment on Timing of Increased Autistic Disorder Cumulative Incidence” I focused on three points. First, the source that MacDonald and Paul used for their California data has a very clear and explicit disclaimer about the fact that those data are not high enough quality for scientific research. Second, the data are exponential. One can fit a “hockey-stick” to exponential data but the results are meaningless. There is no change point in an exponential curve. Third, plotting the data shows that there are change points, but at 1960 and 1974, not 1988 as MacDonald and Paul claimed from fitting one of the exponential regions of data.

In their original paper, MacDonald and Paul point out: “All data were taken from the publications with no attempt to access the original data.” This, as I pointed out in my comment, was unfortunate because the CDDS makes their data available to the public. This would allow one to double check hypotheses, such as whether a “hockey-stick” analysis is appropriate. For many reasons, it is an inappropriate analysis.

First, the California Department of Developmental Services (CDDS) make it clear that these data are not to be used to draw scientific conclusions. From the report where the EPA authors gathered their data:

The information presented in this report is purely descriptive in nature and standing alone, should not be used to draw scientifically valid conclusions about the incidence or prevalence of ASD in California. The numbers of persons with ASD described in this report reflect point-in-time counts and do not constitute formal epidemiological measures of incidence or prevalence. The information contained in this report is limited by factors such as case finding, accuracy of diagnosis and the recording, on an individual basis, of a large array of information contained in the records of persons comprising California’s Developmental Services System. Finally, it is important to note that entry into the California Developmental Services System is voluntary. This may further alter the data presented herein relative to the actual population of persons with autism in California.

If one ignores this major point (as the EPA authors did), there are still other reasons why their analysis method is inappropriate. One big reason is that trying to look for a single “change point” year in California isn’t supported by the data. The fact that autism rates vary dramatically by geography within California (as shown by both Prof. Hertz-Picciotto’s group and Prof Bearman’s group) points away from any universal exposure (such as vaccines). The data I have from the CDDS which breaks down the counts by region only go back to the early 1990’s, so with this and space considerations I did not included these data. These geographic data make it clear that not only do the autism rates vary by region, the time trends of those rates vary a great deal from one region to another. In other words, what is a change point for one region may not be one for another. Applying a single change point to all of California is not warranted using these data.

Another reason why the hockey-stick analysis is inappropriate is the fact that it forces a functional form to the data which is plainly a bad fit. A hockey-stick analysis fits the time trend to two lines with a “change point” where the lines intersect. Unfortunately, the data are exponential. The result is quite remarkable, really, given the geographic variability and the changing social influences on autism rates.

If one takes one of the CDDS datasets (I used one from 2007) and combines it with census type data, one can produce this figure (Figure 1 from the published comment):

Comment-figure

Graphing the data on a log-normal graph such as this shows that the data are exponential. Going all the way back to birth year 1930. It isn’t a simple exponential, though. There is a region around 1960 to 1974 where the growth stalled. It is remarkable that the same time constant fits the data all the way back to 1930, with the exception of this 1960-1974 region.

Fitting exponential data to two lines just doesn’t make sense. There is no “change point” in an exponential. One can force a fit onto exponential data, but it isn’t meaningful.

Using the log-normal plot I supplied one can see that there are change points in the trend. Obvious to any observer. But they are in 1960 and 1974, not in about 1987/88 as MacDonald and Paul calculated.

As is customary, MacDonald and Paul supplied a reply to my comment. In this they make only a very brief reference to the fact that the very document from which they pulled the California data states it is inappropriate to use it the way they did: “We agree with Carey (3) that analysis of long term epidemiological studies would be desirable and that there are a number of potential confounding issues associated with analysis of administrative databases.”

One mistake I made was in not clearly spelling out that fitting a hockey-stick to exponential data is inappropriate. It is obvious, but rather than address this problem MacDonald and Paul state:

Changepoints were determined by fitting a hockey-stick model (10) to the data for each dataset. This approach uses ordered data and piecewise linear regression to split the response variable into two groups. A linear regression line is generated for each group, and the point of intersection for these regression lines and the residual sum of squares for each line are determined. The intersection point that minimizes the residual sum of squares is the changepoint.

Carey (3) used a log transformation of the cumulative incidence to produce a log-linear relationship for the CDDS data of the form: Log (Cumulative Incidence) = B0 + B1 (Year). Subsequently, he states that he could not observe changes in the log-linear relationship of CDDS cumulative incidence at or around our changepoint year of 1989, but no other analysis was performed. Examining original CDDS data in the inset of Carey’s (3) Figure 1, it certainly seems likely that there is a changepoint in the 1985-1990 range, and being unable to observe such a change in the log-linear plot may be purely an artifact of the scaling of the plot. We conducted a changepoint analysis on transformed CDDS data from 1970 to 1997 (from (7)) and found a changepoint in 1984. The shift to an earlier changepoint using the log transformed data may result from stabilization of the variance associated with the transformation, and the resulting shift in the minimization point for the residual sum of squares for the regression line for the larger cumulative incidence values in later years.

It’s an odd response. The authors are focused on defending their original result of a change point in the 1980’s rather than considering the entire new dataset. They ignore the problems inherent in claiming a change point in exponential data, but I should have stressed that more in my comment. Even if MacDonald and Paul claim it is appropriate to make this fit, they ignore the obvious change points in the log-normal graph. Consider the change point at about 1960. It is abundantly clear in the log-normal graph. In the inset of my figure, the linear graph, that change point is still obvious to the eye.

If the real goal of their work was to identify change points there is no reason to ignore those which were (a) outside of their original time span and (b) obvious in a different presentation of the data. This is not just flawed, it is irresponsible. They are ignoring their own stated goal:

As we point out in the paper, while artifacts associated with observed increases in various studies cannot be ruled out, from a precautionary standpoint, it seems prudent to assume that at least some portion of the observed increases in incidence is real and results from the interaction of environmental factors with genetically susceptible populations. Since exposure to environmental factors is potentially preventable, identification of relevant candidate factors should be a research priority.

Why, I would ask, are potential environmental candidates which might involve change points in 1960 and 1974 not important, but one in the late 1980’s is?